Modulation of matrix metalloproteinase activities in periodontitis as a treatment strategy

Periodontology 2000

Volumn 24, Issue 1, 2000, Pages 226-238

  Ryan, Maria Emanuel ^a   Golub, Lorne M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; HYDROXAMIC ACID; MATRIX METALLOPROTEINASE; PROTEINASE INHIBITOR; TETRACYCLINE DERIVATIVE;

ANIMAL; CLINICAL TRIAL; DRUG ANTAGONISM; ENZYME INDUCTION; ENZYMOLOGY; EXTRACELLULAR MATRIX; HUMAN; METABOLISM; OSTEOLYSIS; PERIODONTITIS; REVIEW; UPREGULATION;

ALVEOLAR BONE LOSS; ANIMALS; CHELATING AGENTS; CLINICAL TRIALS; ENZYME INDUCTION; EXTRACELLULAR MATRIX; HUMANS; HYDROXAMIC ACIDS; MATRIX METALLOPROTEINASES; PERIODONTITIS; PROTEASE INHIBITORS; TETRACYCLINES; UP-REGULATION;

EID: 0034304501     PISSN: 09066713     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0757.2000.2240111.x     Document Type: Article

References (99)

1. Ashley R, the SDD Clinical Research Team. Clinical trials of a matrix metalloproteinase inhibitor in human periodontal disease. Ann N YAcad Sci 1999: 878: 335-346.
2. Beck J, Offenbacher S, Williams R, Gibbs P, Garcia R. Periodontitis: a risk factor for coronary heart disease? Ann Periodontol 1998: 3: 142-150.
3. Birkedal-Hansen H, Moore W, Bodden M, Windsor L, Birkedal-Hansen B, DeCarlo A, Engler J. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993: 4: 197-250.
4. Birkedal-Hansen H. Role of matrix metalloproteinases in human periodontal disease. J Periodontol 1993: 64: 474-484.
5. Blundell T. Metalloproteinase super-families and drug design. Struct Biol 1994: 1: 73-75.
6. Borkakoti N, Winkler F, Williams D, D'Arcy A, Broadhurst M, Brown P, Johnson W, Murray E. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Struct Biol 1994: 1: 106-110.
7. Brandt K. Insights into the natural history of osteoarthritis provided by the cruciate-deficient dog. Ann N Y Acad Sci 1994: 732: 199-205.
8. Burns F, Stack M, Gray R, Paterson C. Inhibition of purified collagenase from alkaline-burned rabbit corneas. Invest Ophthalmol Vis Sci 1989: 30: 1569-1575.
9. Caton J, Blieden T, Adams D, Crout R, Hefti A, Killoy W, Nagy R, O'Neal R, Quinones C, Taggart E, Wolff M, Ciancio S. Subantimicrobial doxycycline therapy for periodontitis. J Dent Res 1997: 76: 177.
10. Caton J. Evaluation of Periostat for patient management. Compendium Contin Educ Dent 1999: 20: 451-462.
11. Caton JG, Ciancio SG, Blieden TM, Bradshaw M, Crout RJ, Hefti AF, Massaro JM, Polson AM, Thomas J, Walker C. Treatment with subantimicrobial dose doxycycline improves the efficacy of scaling and root planing in patients with adult periodontitis. J Periodontol 2000: 71: 521-532.
12. Crout R, Lee H, Schroeder K, Crout H, Ramamurthy N, Wiener M, Golub L. The cyclic regimen of low dose doxycycline for adult periodontitis: a preliminary study. J Periodontol 1996: 67: 506-514.
13. DeCarlo A, Grenett H, Harbar G, Windsor J, Bodden M, Birkedal-Hansen B, Birkedal-Hansen H. Introduction of matrix metalloproteinases and a collagen-degrading phenotype in fibroblasts and epithelial cells by secreted Porphyromonas gingivalis proteinase. J Periodontal Res 1998: 33: 408-420.
14. Drisko C. Non-surgical pocket therapy: pharmacotherapeutics. Ann Periodontol 1996: 1: 491-566.
15. Evans R, Klausen B, Sojar H, Ramamurthy N, Evans M, Dyer D, Genco R. Immunization with Porphyromonas gingivalis fimbriae and a synthetic fimbrial peptide. Washington, DC: Am Soc Microbiol, 1994.
16. Fullmer H, Gibson W. Collagenolytic activity of gingivae of man. Nature 1966: 209: 728-729.
17. Galardy R, Grobelny D, Kortylewicz Z, Poncz L. Inhibition of human skin fibroblast collagenase by phosphorus-containing peptides. Matrix 1992: suppl 1: 259-262.
18. Galardy R, Cassabonne M, Giese C, Gilbert J, Lapierre F, Lopez H, Schaeffer M, Stack R, Sullivan M, Summers B, Tressler R, Tyrrell D, Wee J, Allen S, Castellot J, Barletta J, Schultz G, Fernandez L, Fisher S, Cui TY, Foellmer H, Grobelny D, Holleran W. Low molecular weight inhibitors of corneal ulceration. Ann N Y Acad Sci 1994: 732: 315-323.
19. Gangbar S, Overall C, McCulloch C, Sodek J. Identification of polymorphonuclear leukocyte collagenase and gelatinase activity in mouthrinse samples: correlations with periodontal disease activity in adult and juvenile periodontitis. J Periodontal Res 1990: 25: 257-267.
20. Gearing A, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson A, Drummond A, Galloway W, Gilbert R, Gordon J, Leber T, Mangan M, Miller K, Mayee P, Owen K, Patel S, Thomas W, Wells G, Wood L, Wooley K. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature 1994: 370: 555-557.
21. Genco RJ, Offenbacher S, Beck J, Rees T. Cardiovascular disease and oral infections, In: Rose LF, Genco RJ, Cohen DW, Mealy BL, ed. Periodontal medicine. St. Louis: BC Decker, 1999.
22. Giannobile W, Lynch S, Denmark R, Paquette D, Fiorellini J, Williams R. Crevicular fluid osteocalcin and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) as markers of rapid bone turnover in periodontitis. J Clin Periodontol 1995: 22: 903-910.
23. Golub L, Seigel K, Ramamurthy N, Mandel I. Some characteristics of collagenase activity in gingival crevicular fluid and its relationship to gingival disease in humans. J Dent Res 1976: 55: 1049-1057.
24. Golub LM, Lee HM, Lehrer G, Nemiroff A, McNamara TF, Kaplan R, Ramamurthy NS. Minocycline reduces gingival collagenolytic activity during diabetes: preliminary observations and a proposed new mechanism of action. J Peridontal Res 1983: 18: 516-526.
25. Golub L, Ramamurthy N, McNamara T, Gomes B, Wolff M, Casino A, Kapoor A, Zambon J, Ciancio S, Schneir M, Perry H. Tetracyclines inhibit tissue collagenase activity. J Periodontal Res 1984: 19: 651-655.
26. Golub L, Wolff M, Lee H, McNamara T, Ramamurthy N, Zambon J, Ciancio S. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J Periodontal Res 1985: 20: 12-23.
27. Golub L, McNamara T, D'Angelo G, Greenwald R, Ramamurthy N. A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity. J Dent Res 1987: 66: 1310-1314.
28. Golub L, Ciancio S, Ramamurthy N, Leung M, McNamara T. Low dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans. J Periodontal Res 1990: 25: 321-330.
29. Golub L, Ramamurthy N, McNamara T, Greenwald R, Rifkin B. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 1991: 2: 297-322.
30. Golub L, Suomalainen K, Sorsa T. Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent 1992: 2: 80-90.
31. Golub L, Wolff M, Roberts S, Lee HM, Leung M, Payonk G. Treating periodontal diseases by blocking tissue-destructive enzymes. J Am Dent Assoc 1994: 125: 163-169.
32. Golub L, Evans R, McNamara T, Lee H, Ramamurthy N. A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone loss in Porphyromonas gingivalis-induced periodontitis in rats. Ann N Y Acad Sci 1994: 732: 96-111.
33. Golub L, Sorsa T, Lee HM, Ciancio S, Sorbi D, Ramamurthy N. Doxycyclineinhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol 1995: 21: 1-9.
34. Golub L, Lee H, Greenwald R, Ryan M, Sorsa T, Salo T, Giannobile W. A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and bone-type collagenase in gingival crevicular fluid during adult periodontitis. Inflamm Res 1997: 4: 310-319.
35. Golub L, Lee H, Ryan M, Giannobile W, Payne J, Sorsa T. Tertacyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998: 12: 12-26.
36. Gomes B, Golub L, Ramamurthy N. Tetracyclines inhibit parathyroid hormone induced bone resorption in organ culture. Experientia 1984: 40: 1273-1275.
37. Gomez R, Romero R, Edwin SS, David C. Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intraamniotic infection. Infect Dis Clin North Am 1997: 11: 135-176.
38. Gordon J, Walker C, Murphy J, Goodson J, Socransky S. Tetracycline: Levels achievable in gingival crevice fluid and in vitro effect on subgingival microorganisms. I. Concentrations in crevicular fluid after repeated doses. J Periodontol 1981: 52: 609-612.
39. Greenwald R. Tetracyclines may have potential benefit in rheumatoid arthritis but not for the reasons you think. J Clin Rheumatol 1995: 1: 185-189.
40. Greenwald R, Golub L, Ramamurthy N, Chowdhury M, Moak S, Sorsa T. In vitro sensitivity of three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone 1998: 22: 33-38.
41. Gross J, Lapiere C. Collagenolytic activity in amphibian tissues: A tissue culture assay. Proc Natl Acad Sci U S A 1962: 48: 1014-1020.
42. Haerian A, Adonogianaki E, Mooney J, Docherty J, Kinane D. Gingival crevicular stromelysin, collagenase and tissue inhibitor of metalloproteinase levels in healthy and diseased sites. J Clin Periodontol 1995: 22: 505-509.
43. Hall T, Chambers T. Molecular aspects of osteoclast function. Inflamm Res 1996: 45: 1-9.
44. Hill P, Docherty A, Bottomley K, O'Connell J, Morphy J, Reynolds J, Meikle M. Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase. Biochem J 1995: 388: 167-175.
45. Hodgson J. Remodelling MMPIs. Biotechnol 1995: 13: 554-557.
46. Ingman T. Neutral proteinases in periodontal diseases: functional and immunohistochemical assessment. Academic dissertation, University of Helsinki, Finland, 1994.
47. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996: 271: 1544-1550.
48. Kornman K, Karl E. The effect of long-term low-dose tetracycline therapy on the subgingival microflora in refractory adult periodontitis. J Periodontol 1982: 53: 604-610.
49. Lee W, Aitken S, Sodek J, McCulloch C. Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: role of active enzyme in human periodontitis. J Periodontal Res 1995: 30: 23-33.
50. 1-Proteinase inhibitor in gingival crevicular fluid of humans with adult periodontitis: serpinolytic inhibition by doxycycline. J Periodontal Res 1997: 32: 9-19.
51. Lockwood CJ, Kuczynski E. Markers of risk for preterm delivery. J Perinat Med 1999: 27: 5-20.
52. Lovejoy B, Cleasby A, Hassell A, Longely K, Luther M, Weigl D, McGeehan G, McElroy A, Drewry D, Lambert M, Jordan S. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 1994: 263: 375-377.
53. Mallya S, Hall J, Lee HM, Roemer E, Simon S, Golub L. Interaction of matrix metalloproteinases with serine proteinase inhibitors: New potential roles for matrix metalloproteinase inhibitors. Ann N Y Acad SCi 1994: 732: 303-314.
54. Martel-Pelletier J, Pelletier J. Wanted-the collagenase responsible for the destruction of the collagen network in human cartilage. Br J Rheumatol 1996: 35: 818-820.
55. Matrisian L. The matrix-degrading metalloproteinases. BioEssays 1992: 14: 455-463.
56. McCulloch C. Collagenolytic enzymes in gingival crevicular fluid as diagnostic indicators of periodontitis. Ann N Y Acad Sci 1994: 732: 152-164.
57. McGeehan G, Becherer J, Bast RJ, Boyer C, Champion B, Connolly K, Conway J, Furdon P, Karp S, Kidao S, McElroy A, Nichols J, Pryzwansky K, Schoenen F, Sekut L, Truesdale A, Verghese M, Warner J, Ways J. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994: 370: 558-561.
58. McNamara T, Golub L, Yu Z, Ramamurthy N. Reduced doxycycline bloodlevels in humans fail to promote resistant organisms. In: International Conference on Periodontal Disease: Pathogens and Host Immune Responses, 1990, Osaka, Japan: 100, abstr B54.
59. Mealey B. Diabetes mellitus, In: Rose LF, Genco RJ, Cohen DW, Mealy BL, ed. Periodontal medicine. St. Louis: BC Decker, 1999.
60. Nagai Y, Hattori S, Odake S, Okayama T, Obata M, Morikawa T. Preparation of peptidyl hydroxamic acid derivatives which inhibit interstitial collagenases. Matrix 1992: suppl 1: 313.
61. Offenbacher S, Jared HL, O'Reilly PG, Wells SR, Salvi GE, Lawrence HP, Socransky SS, Beck JD. Potential pathogenic mechanisms of periodontitis-associated pregnancy complications. Ann Periodontol 1998: 3: 233-250.
62. Overall C, Sodek J, McCulloch A, Birek P. Evidence for polymorphonuclear leukocyte collagenase and 92-kilodalton gelatinase in gingival crevicular fluid. Infect Immun 1991: 59: 4687-4692.
63. Page R. The pathobiology of periodontal disease may affect systemic diseases: inversion of a paradigm. Ann Periodontol 1998: 3: 108-120.
64. Pascale D, Gordon J, Lamster I, Mann P, Seiger M, Arndt W. Concentration of doxycycline in human gingival fluid. J Clin Periodontol 1986: 13: 841-844.
65. Ries C, Petrides P. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem 1995: 376: 345-355.
66. Rifkin B, Vemillo A, Golub L. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs. J Periodontol 1993: 64: 819-827.
67. Rugg T. Matrix metalloproteinase inhibition as a novel anticancer strategy - review of preclinical and clinical data with Batimastat and Marimastat. In: Protease inhibitors in inflammation. San Diego, CA.
68. Ryan M, Ramamurthy N, Golub L. Matrix metalloproteinases and their inhibition in periodontal treatment. Curr Opin Periodontol 1996: 3: 85-96.
69. Ryan ME. Host response in diabetes-associated periodontitis: effects of tetracycline analogues. Dissertation. State University of New York at Stony Brook, 1998.
70. Ryan M, Ashley R. How do tetracyclines work? Adv Dent Res 1998: 12: 149-151.
71. Sakellari D, Goodson J, Socransky S, Kolokotronis A, Konstantinidis A. Concentration of 3 tetracyclines in plasma, GCF and saliva. J Dent Res 1997: 76: 176.
72. Sasaki T, Ramamurthy N, Golub L. Tetracycline administration increases collagen synthesis in osteoblasts of streptozotocin-induced diabetic rats: a quantitative radiographic study. Calcif Tissue Int 1992: 50: 411-419.
73. Sato T, del Carmen M, Hou P, Heegaard M, Kumegawa M, Forged T, Delaisse J. Identification of the membrane-type matrix metalloproteinase MT1-MMP in osteoclasts. J Cell Sci 1997: 110: 589-596.
74. Schneir M, Ramamurthy N, Golub L. Minocycline treatment of diabetic rats increases skin collagen production and mass; possible causative mechanisms. Matrix 1990: 10: 112-123.
75. Schwartz M, Venkataraman S, Libby A, Mookhtiar K, Mallya S, Van Wart H, Birkedal-Hansen H. Sulfur-based inihibitors for matrix metalloproteinases. Matrix 1992: suppl 1: 309-310.
76. Seftor R, Seftor E, DeLarco J, Kleiner D, Leferson J, Stetler-Stevenson W, McNamara T, Golub L, Hendrix M. Chemically-modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 1998: 16: 217-225.
77. Shapira L, Soskolne W, Houri Y, Barak V, Halabi A, Stabholz A. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infect Immun 1996: 64: 825-828.
78. Smith G, Brandt K, Hasty K. Procollagenase is reduced to inactive fragments upon activation in the presence of doxycycline. Ann N Y Acad Sci 1994: 732: 436-438.
79. Sodek J, Overall C. Matrix metalloproteinases in periodontal tissue remodelling. Matrix 1992: Suppl: 352-362.
80. Sorsa T, Uitto VJ, Suomolainen M, Vauhkonen M, Lindy S. Comparison of interstitial collagenases from human gingiva, sulcular fluid and polymorphonuclear leukocytes. J Periodontal Res 1988: 23: 386-393.
81. Sorsa T, Ding Y, Salo T, Lauhio A, Teronen O, Ingman T, Ohtani H, Andoh N, Takeha S, Konttinen Y. Effects of tetracyclines on neutrophil, gingival and salivary collagenases: a functional and western blot assessment with special references to their cellular sources in periodontal diseases. Ann N Y Acad Sci 1994: 732: 112-131.
82. Sorsa T, Mantyla P, Ronka H, Ronka H, Kallio P, Kallis GB, Lundqvist C, Kinane DF, Salo T, Golub LM, Teronen O, Tikanoja S. Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. Ann N Y Acad Sci 1999: 878: 130-140.
83. Stolow MA, Bauzon DD, Li J, Sedgwick T, Lian VCT, Qingxiang AS, Shi YB. Identificantion and characterization of a novel collagenase in Xenopus laevis: possible roles during frog development. Mol Biol Cell 1996: 7: 1471-1483.
84. Talonpoika J, Hamalainen M. Type I collagen carboxyterminal telopeptide in human gingival crevicular fluid in different clinical conditions and after periodontal treatments. J Clin Periodontol 1994: 25: 320-326.
85. Teronen O, Konttinen Y, Lindqvist C, Salo T, Ingman T, Lauhio A, Ding Y, Santavirta S, Sorsa T. Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate. J Dent Res 1997: 76: 1529-1537.
86. Teronen O, Konttinen Y, Lindqvist C, Salo T, Ingman T, Lauhio A, Ding Y, Santavirta S, Valleala H, Sorsa T. Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate). Calcif Tissue Int 1997: 61: 59-61.
87. Tezuka KI, Nemoto K, Tezuka Y, Sato T, Ikeda Y, Kobori M, Kawashima H, Eguchi H, Hakeda Y, Kumegawa M. Identification of matrix metalloproteinase 9 in rabbit osteoclasts. J Biol Chem 1994: 269: 15006-15009.
88. Thomas J, Metheny RJ, Karakiozis JM, Wetzel JM, Crout R. Long-term subantimicrobial doxycycline (Periostat) as adjunctive management in adult periodontitis: Effects of subgingival bacterial population dynamics. Adv Dent Res 1998: 12: 32-39.
89. Thompson R, Harvin H, Liao S, Callery M. Doxycycline suppresses serum tumor necrosis factor-α (TNF-α) levels in lipopolysaccharide-challenged rats. Surg Infect Soc Meeting 1996.
90. Uitto V, Suomalainen K, Sorsa T. Salivary collagenase. Origin, characteristics and relationship to periodontal health. J Periodontal Res 1990: 25: 135-142.
91. Uitto VJ, Firth J, Nip L, Golub L. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann N Y Acad Sci 1994: 732: 140-151.
92. Uitto VJ, Airola K, Vaalamo M, Johansson N, Putnins EE, Firth JD, Salonen J, Lopez-Otin C, Saarialho-Kere U, Kahari VM. Collagenase-3 (matrix metalloproteinase-13) expression is induced in oral mucosal epithelium during chronic inflammation. Am J Pathol 1998: 152: 1489-1499.
93. Vernillo A, Ramamurthy N, Golub L, Rifkin B. The nonantimicrobial properties of tetracyclines for the treatment of periodontal disease. Curr Opin Periodontol 1994: 1: 111-118.
94. Vernillo A, Rifkin B. Effects of tetracyclines on bone metabolism. Adv Dent Res 1998: 12: 56-62.
95. Woessner J Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991: 5: 2145-2154.
96. Woessner J Jr. The family of matrix metalloproteinases. Ann N Y Acad Sci 1994: 732: 11-21.
97. Wucherpfennig A, Li YP, Stetler-Stevenson W, Rosenberg A, Stashenko P. Expression of 92 kD Type IV collagenase/gelatinase B in human osteoclasts. J Bone Miner Res 1994: 9: 549-556.
98. Yu L, Smith G, Hasty K, Brandt K. Doxycycline inhibits Type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. J Rheumatol 1991: 18: 1450-1452.
99. Yu Z, Leung M, Ramamurthy N, McNamara T, Golub L. HPLC determination of a chemically-modified non-antimicrobial tetracycline: biologic implications. Biochem Med 1992: 47: 10-20.